Introduction
============

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths in the modern world, and its incidence continues to increase.[@b1-ott-10-5363] Chronic hepatitis B virus (HBV) infection remains a major cause of HCC development (especially in Asia) either through direct transactivation, viral integration, or indirectly through inflammation, fibrosis, or cirrhosis.[@b2-ott-10-5363],[@b3-ott-10-5363] Growing evidence has shown that antiviral therapy with nucleoside analogs (NAs) can reduce the risk of HCC development in patients with chronic HBV infection.[@b4-ott-10-5363],[@b5-ott-10-5363] According to the current guidelines for the management of HCC, surgical resection should be considered as the first-line treatment for patients with resectable tumors and preserved liver function.[@b6-ott-10-5363],[@b7-ott-10-5363] With advances in surveillance programs, early diagnosis, and surgical technologies, the long-term postoperative survival of patients with early-stage HCC has improved, but is still unsatisfactory due to the high recurrence rate. Therefore, how to decrease HCC recurrence after curative resection merits further attention.

In patients with resected HBV-related HCC, factors including high viral replication status, active inflammation, subsequent damage, and regeneration of hepatocytes are associated with an increased risk of recurrence and adverse long-term survival outcomes.[@b8-ott-10-5363]--[@b10-ott-10-5363] Further, sustained low HBV load predicts good long-term recurrence-free survival (RFS) and overall survival (OS).[@b11-ott-10-5363] Recently, several pioneering studies used antiviral therapy with NAs (NA therapy) to treat patients with HBV-related HCC after curative resection and assessed the effect of such therapy on the long-term postoperative survival outcomes.[@b12-ott-10-5363]--[@b36-ott-10-5363] Some trials reported significant postoperative survival benefits, but others failed to confirm such outcomes. Indeed, the previous meta-analyses on this issue did not exclude patients who received NA therapy before the diagnosis of HBV-related HCC, which may affect the natural course of HBV-related HCC.[@b37-ott-10-5363] Compared to locoregional therapy including radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), and transcatheter arterial embolization (TAE), surgical resection can usually achieve relatively complete elimination of HCC lesions and satisfied margin of normal liver tissue which is very important to avoid potential tumor tissue remnant and potentially benefits the prognosis of patients.[@b38-ott-10-5363]--[@b40-ott-10-5363] Patients who received locoregional treatments instead of curative resection for the initial treatment of HCC had not been excluded in the previous meta-analyses, which may have potentially biased the interpretation of survival outcomes.[@b41-ott-10-5363]--[@b45-ott-10-5363] Otherwise, non-English articles were all excluded in previous meta-analyses, and this search strategy may not be sufficiently comprehensive since HBV infection is the main cause of HCC in Asia-Pacific region, and Chinese, Korean, and Japanese articles may contribute significantly to the meta-analysis. Therefore, to investigate this important issue, we performed a more comprehensive meta-analysis to evaluate the effect of NA therapy after curative resection on the long-term postoperative survival of patients with HBV-related HCC.

Materials and methods
=====================

Data sources and search strategy
--------------------------------

A systematic literature search was performed up to August 2017 using MEDLINE, PubMed, Embase, and Cochrane Library with no limits. The search strategy involved the Medical Subject Heading (MeSH) terms: "hepatitis B," "HBV," "antiviral," "nucleotide," "nucleotide analog," "lamivudine," "adefovir," "entecavir," "telbivudine," "hepatocellular carcinoma," "HCC," "liver cancer," "hepatic cancer," "liver resection," "surgical resection," "radical resection," "curative resection," "hepatic resection," and "hepatectomy," combined with free text words. The bibliographies of all retrieved review articles and primary studies were manually searched for more relevant studies. For studies with duplicate publications from the same cohort, the most recent comprehensive publication was included.

Study selection
---------------

All clinical studies, including randomized controlled trials (RCTs) and prospective or retrospective cohort studies, were selected if they met the following criteria: 1) enrolled patients who were diagnosed with HBV-related HCC and underwent curative resection as the initial treatment; 2) enrolled patients underwent no other forms of antitumor therapy before curative resection, such as local ablation therapy, regional or systemic chemotherapy, molecular target therapy, or immunotherapy; 3) consisted of one or more groups treated with NA therapy and an untreated control group; 4) reported at least long-term results of OS or RFS for outcome measures; 5) had been published with full-text accessible.

Studies were excluded if they met one or more of the following criteria: 1) included patients who received NA therapy before the diagnosis of HBV-related HCC; 2) included patients with combined infection of other hepatitis viruses; 3) included patients with drug abuse or alcohol consumption; 4) nonhuman studies, abstracts, editorials, letters, case reports, reviews, and studies not clearly reporting the outcomes of interest.

Outcome measures
----------------

The primary analysis focused on OS of HBV-related HCC after curative resection, and postoperative RFS served as secondary outcome.

Data extraction
---------------

Parameters regarding the following information were extracted in a standardized data extraction form: 1) study characteristics: reference, year of publication, country of origin, and study design; 2) patient characteristics: sample size, age, gender, hepatitis B e-antigen (HBeAg) status, and Child--Pugh classification; 3) tumor characteristics: tumor size and number; 4) outcomes of the antiviral therapy group and the control group: OS and RFS; 5) potential sources of heterogeneity. Any discrepancy in the extraction process was resolved by discussion and consensus.

Quality assessment
------------------

The quality of each trial was assessed independently by two study investigators (X-XC and X-RY). The Jadad scale was used to score the methodological quality of RCTs based on the following items: randomization (0−2 points), blinding (0−2 points), and dropouts and withdrawals (0−1 point). A modified Newcastle--Ottawa Scale was used to assess non-RCTs across the following three factors: patient selection (0−2 stars), comparability of the cohort (0−2 stars), and outcome assessment (0−2 stars).[@b46-ott-10-5363]

Statistical analysis
--------------------

The meta-analysis was performed by using Review Manager (version 5.2), which was provided by the Cochrane Collaboration (The Nordic Cochrane Centre, Copenhagen, Denmark). Long-term outcomes (survival analysis) were analyzed by calculating the hazard ratio (HR) with 95% confidence interval (95% CI). HRs of the OS or RFS were calculated and combined using the data extracted from Kaplan--Meier curves; HR \<1 represented survival benefits favoring the antiviral therapy group. A random-effect model (DerSimonian and Laird's method) was used to compare the overall effect estimates.

Statistical heterogeneity was explored by the *χ*^2^ and *I*^2^ statistics. *I*^2^\<25% was considered to reflect low heterogeneity, an *I*^2^ value between 25% and 50% was considered to reflect moderate heterogeneity, and *I*^2^\>50% was considered to reflect high heterogeneity. Heterogeneity was considered statistically significant when the Cochrane *Q* test *P*\<0.10. Two-sided value of *P*\<0.05 was considered statistically significant. A funnel plot was conducted to screen for potential publication bias.

In addition, a sensitivity analysis was performed to assess the effect of individual studies on the pooled estimates. To anticipate potential heterogeneity among the included studies, subgroup analysis was performed for the following study-related variables if the necessary data were provided: 1) NA type; 2) viral load (baseline HBV DNA level ≥20,000 IU/mL versus \<20,000 IU/mL); 3) fully preserved hepatic function (Child class A).

Results
=======

Characteristics of identified studies
-------------------------------------

A total of 360 potentially relevant studies were identified through database searching and other sources. After detailed screening, based on the inclusion and exclusion criteria, 25 references involving 26 studies (two RCTs and 24 non-RCTs) were included for the final meta-analysis.[@b12-ott-10-5363]--[@b36-ott-10-5363] One study was a two-stage longitudinal clinical study, which included a first-stage non-RCT to assess the effect of NA therapy on the postoperative prognosis of HBV-related HCC and a second-stage RCT to validate the initial result.[@b20-ott-10-5363] Furthermore, propensity score matching (PSM) analysis was performed in one retrospective study to reduce patient selection bias, and we only extracted the data after PSM for the current meta-analysis.[@b15-ott-10-5363] The detailed study screening and selection process is shown in [Figure 1](#f1-ott-10-5363){ref-type="fig"}.

A total of 9,009 patients with resected HBV-related HCC were included in the analysis, 2,546 of whom received NA therapy (antiviral therapy group), whereas the other 6,463 patients received no treatment (control group). [Table 1](#t1-ott-10-5363){ref-type="table"} lists the baseline characteristics of the included studies and the main features of the enrolled patients.

Antiviral therapy and virological response
------------------------------------------

In the 26 included studies, lamivudine was the most commonly used antiviral drug, followed by entecavir and adefovir. When lamivudine resistance occurred, adefovir was added or entecavir was used instead. Three studies reported HBV DNA suppression rates, and NA therapy was associated with significantly higher HBV DNA suppression rate at 1, 2, 3, and 5 years.[@b13-ott-10-5363],[@b14-ott-10-5363],[@b16-ott-10-5363],[@b26-ott-10-5363],[@b29-ott-10-5363],[@b36-ott-10-5363] In the antiviral therapy group, the HBV DNA suppression rate ranged from 51.3% to 87.2% at 1 year, from 62.7% to 98.0% at 2 years, from 67.2% to 91.7% at 3 years, and 92.8% at 5 years of NA therapy. The cumulative HBeAg seroconversion rate at 1 year ranged from 12.0% to 57.2% in the antiviral therapy group.[@b14-ott-10-5363],[@b16-ott-10-5363]

Primary outcome: OS
-------------------

A total of 17 studies reported the comparative data for post-operative OS. Meta-analysis of these studies revealed that the NA therapy was significantly associated with higher OS (HR: 0.58; 95% CI: 0.51--0.67; *P*\<0.00001; [Figure 2A](#f2-ott-10-5363){ref-type="fig"}). Moderate heterogeneity was detected in the analysis (*P*=0.04, *I* [@b2-ott-10-5363]=40%). However, after pooling studies using one type of NA, no heterogeneity was observed within subgroups of studies ([Figure 3](#f3-ott-10-5363){ref-type="fig"}).

While the subgroup analysis of patients with high baseline HBV DNA level (≥20,000 IU/mL) showed stable results (HR: 0.69; 95% CI: 0.52--0.92; *P*=0.01) with no heterogeneity among studies, the subgroup analysis of patients with low baseline HBV DNA level (\<20,000 IU/mL) indicated no significant difference between the antiviral therapy group and the control group (HR: 0.80; 95% CI: 0.38--1.68; *P*=0.56; [Figure 4A](#f4-ott-10-5363){ref-type="fig"}). Stratified meta-analysis of fully preserved hepatic function (Child class A) showed stable results with no heterogeneity ([Figure 5A](#f5-ott-10-5363){ref-type="fig"}).

Secondary outcome: RFS
----------------------

The selected 25 studies reported the comparative data for postoperative RFS. Meta-analysis of these studies showed that patients with NA therapy had a significantly increased RFS after surgery (HR: 0.68; 95% CI: 0.63--0.74; *P*\<0.00001). Moderate heterogeneity was detected in the analysis (*P*=0.08, *I* [@b2-ott-10-5363]=30%; [Figure 2B](#f2-ott-10-5363){ref-type="fig"}). However, after pooling studies using one type of NA, only a little heterogeneity was observed within subgroups of studies ([Figure 6](#f6-ott-10-5363){ref-type="fig"}).

According to subgroup analysis, patients with high base-line HBV DNA level showed stable results (HR: 0.58; 95% CI: 0.49--0.70; *P*\<0.00001) with on heterogeneity among studies, whereas results from patients with low baseline HBV DNA level showed no significant difference between the antiviral therapy group and the control group (HR: 0.86; 95% CI: 0.51--1.46; *P*=0.57) with moderate heterogeneity among studies ([Figure 4B](#f4-ott-10-5363){ref-type="fig"}). Stratified meta-analysis of fully preserved hepatic function (Child class A) showed stable results with high heterogeneity ([Figure 5B](#f5-ott-10-5363){ref-type="fig"}).

Liver function reserve at HCC recurrence and subsequent treatment for recurrence
--------------------------------------------------------------------------------

Two studies reported significantly better liver function in the antiviral therapy group compared to the control group at the time of HCC recurrence.[@b13-ott-10-5363],[@b15-ott-10-5363] Similarly, several studies reported significantly improved liver function in the antiviral therapy group compared to the control group at 6 months after surgery;[@b20-ott-10-5363],[@b25-ott-10-5363],[@b26-ott-10-5363],[@b28-ott-10-5363] Li et al's[@b16-ott-10-5363] study also reported a significant residual liver volume improvement in the antiviral therapy group compared to the control group at 6 months after surgery. Two studies reported a significantly higher amenability rate of radical retreatment (eg, surgical resection or local ablation therapy) for HCC recurrence in the antiviral therapy group due to better liver function reserve than that of the control group.[@b13-ott-10-5363],[@b15-ott-10-5363]

Publication bias
----------------

[Figure 7](#f7-ott-10-5363){ref-type="fig"} illustrates a funnel plot of the included studies comparing postoperative RFS in HBV-related HCC patients with or without NA therapy. Visual inspection of the funnel plot revealed asymmetry, and Begg's test for publication bias showed statistically significant results which indicated possibility of publication bias (*z*=2.73, *P*=0.006). Subsequently, trim and fill method was used to correct and identify whether the asymmetry funnel plot was caused by publication bias. The results showed that no study was missing in the iterative algorithm and the effect size of the meta-analysis after trimming and filling was exactly same as the primary results, which indicated that there was no publication bias and the asymmetry funnel plot may not be caused by publication bias.

Discussion
==========

Tumor recurrence is the most common cause of mortality for HCC patients after curative resection.[@b47-ott-10-5363] Despite the advances in surveillance programs, surgical technologies, and multidisciplinary treatments, there are still no adjuvant therapy options that effectively prevent HCC recurrence after curative resection. Most of the well-known risk factors for HCC recurrence, such as tumor characteristics, liver cirrhosis, and alpha fetoprotein level, are irreversible.[@b48-ott-10-5363] However, HBV status is an important risk factor for HCC recurrence that can be reversed by NA therapy. Thus, the exact effect of NA therapy on patients with HBV-related HCC after curative resection becomes a subject of great interest to hepatobiliary surgeons or physicians, and several studies have been performed recently, but the results are inconsistent. Otherwise, there is still not enough convincing evidence to support this issue because of the potential bias mentioned earlier in the previous studies or meta-analyses. Therefore, we conducted the current study, a more comprehensive meta-analysis, to assess the exact effect of NA therapy after curative resection on the long-term survival of patients with HBV-related HCC as far as possible.

The current meta-analysis demonstrated that NA therapy significantly improved the RFS of patients after surgical resection for HBV-related HCC, which suggested that NA therapy can prevent or delay the recurrence of HBV-related HCC. Recent studies have demonstrated that sustained viremia may impair tumor immune surveillance and favor the development of hepatocellular carcinogenesis,[@b49-ott-10-5363],[@b50-ott-10-5363] and chronic hepatitis activity and liver inflammation induced by immune response were associated with HCC recurrence after radical resection.[@b51-ott-10-5363],[@b52-ott-10-5363] Similarly, other studies found that high HBV load and HBV mutation promote the growth and metastasis of HCC,[@b17-ott-10-5363],[@b53-ott-10-5363],[@b54-ott-10-5363] and the HBV X protein promotes the invasive and metastatic potential of HCC.[@b20-ott-10-5363],[@b55-ott-10-5363]--[@b57-ott-10-5363] Therefore, the beneficial effect of NA therapy on HCC recurrence may be associated with the inhibition of these viral factors. Due to moderate heterogeneity that was detected among eligible studies, subgroup analyses were performed. After pooling studies using one type of NAs, only a little heterogeneity was observed. That may be partly attributed to the different viral suppression effect of different types of NAs which can further affect the tumor recurrence of HBV-related HCC. In the subgroup analyses of patients with different viral load, NA therapy can significantly prolong RFS in patients with high baseline HBV DNA level (≥20,000 IU/mL) with no heterogeneity, but not in patients with low baseline HBV DNA level (\<20,000 IU/mL) with moderate heterogeneity. The results indicated that HCC patients with low baseline HBV DNA level may not significantly benefit from NA therapy as patients with high baseline HBV DNA level did. However, as there was moderate heterogeneity in the subgroup analysis of patients with low baseline HBV DNA level (\<20,000 IU/mL), the findings are not conclusive and further high-quality studies are needed.

In this study, we also found that NA therapy can significantly improve the OS of patients with HBV-related HCC after surgical resection. The beneficial effect of NA therapy in preventing or delaying HCC recurrence contributes to better OS. Further, several studies have reported that NA therapy is effective in suppressing viral replication, modulating liver function, and increasing residual liver volume after radical resection.[@b13-ott-10-5363],[@b15-ott-10-5363],[@b16-ott-10-5363],[@b20-ott-10-5363] These effects may not only affect survival directly but also significantly improve the tolerance of patients to receive subsequent therapy (especially repeat surgical resection) after HCC recurrence which leads to a significant improvement in OS. Subgroup analyses were also conducted because of the moderate heterogeneity among studies. After pooling studies using one type of NA, no heterogeneity was observed among studies. In the subgroup analyses of patients with different viral load, NA therapy can significantly prolong OS in patients with high baseline HBV DNA level (≥20,000 IU/mL) with no heterogeneity, but not in patients with low baseline HBV DNA level (\<20,000 IU/mL) with moderate heterogeneity. Smaller size was one factor that led to nonsignificant groups of patients with low baseline HBV DNA level (\<20,000 IU/mL). Moreover, it has been identified that HCC patients with persistently low HBV DNA levels had better survival results compared to those with high HBV DNA levels. After antiviral therapy, groups of HCC patients with high HBV DNA levels always could achieve a more substantial reduction in HBV DNA load, as compared to groups of HCC patients with low HBV DNA levels. Therefore, HCC patients with low HBV DNA levels may not significantly benefit from antiviral therapy compared to patients with high HBV DNA levels. However, as only one study was included in the subgroup analysis of patients with low baseline HBV DNA level (\<20,000 IU/mL), more quality studies are needed to draw a definitive conclusion.

Nonetheless, there are several limitations to the current meta-analysis. First, most of the included studies were non-RCTs; the potential confounding factors in these studies may decrease the reliability of the results, even for the well-analyzed cohort studies. Second, several indirect data acquisition methods were used in the meta-analysis, which may have effects on the outcomes. Finally, moderate heterogeneity existed in the meta-analysis; the variation in HBV status, type of NA therapy, Child--Pugh class, and tumor stage may be responsible for the heterogeneity.

Conclusion
==========

The current meta-analysis suggests that antiviral therapy with NAs significantly improves the survival outcomes of patients with HBV-related HCC after curative resection, especially for patients with high HBV DNA level. To further investigate the promising effects of antiviral therapy with NAs on patients with low HBV DNA level, high-quality studies are needed.
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![Flowchart of search strategy for meta-analysis study selection.\
**Abbreviations:** HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HDV, hepatitis D virus.](ott-10-5363Fig1){#f1-ott-10-5363}

![Forest plots for postoperative survival outcomes.\
**Notes:** (**A**) Meta-analysis of OS. (**B**) Meta-analysis of RFS. \*Study of Yin et al (2013)[@b20-ott-10-5363] was a two-stage longitudinal clinical study which included a first stage pro study and a second stage RCT. Therefore, the first stage pro study was defined as Yin et al (2013a)[@b20-ott-10-5363] and the second stage RCT was defined as Yin et al (2013b)[@b20-ott-10-5363].\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; IV, inverse variance; OS, overall survival; RFS, recurrence-free survival; SE, standard error.](ott-10-5363Fig2){#f2-ott-10-5363}

![Stratified meta-analysis of OS according to the type of NAs.\
**Note:** \*Study of Yin et al (2013)[@b20-ott-10-5363] was a two-stage longitudinal clinical study which included a first stage pro study and a second stage RCT. Therefore, the first stage pro study was defined as Yin et al (2013a)[@b20-ott-10-5363] and the second stage RCT was defined as Yin et al (2013b)[@b20-ott-10-5363].\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; IV, inverse variance; NAs, nucleoside analogs; OS, overall survival; SE, standard error.](ott-10-5363Fig3){#f3-ott-10-5363}

![Stratified meta-analysis of postoperative survival outcomes according to viral load (baseline HBV DNA level ≥20,000 IU/mL versus \<20,000 IU/mL).\
**Notes:** (**A**) Meta-analysis of OS. (**B**) Meta-analysis of RFS.\
**Abbreviations:** CI, confidence interval; HBV, hepatitis B virus; HR, hazard ratio; IV, inverse variance; OS, overall survival; RFS, recurrence-free survival; SE, standard error.](ott-10-5363Fig4){#f4-ott-10-5363}

![Subgroup analysis on patients with fully preserved hepatic function (Child class A).\
**Notes:** (**A**) Meta-analysis of OS. (**B**) Meta-analysis of RFS.\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; IV, inverse variance; OS, overall survival; RFS, recurrence-free survival; SE, standard error.](ott-10-5363Fig5){#f5-ott-10-5363}

![Stratified meta-analysis of RFS according to the type of NAs.\
**Note:** \*Study of Yin et al (2013)[@b20-ott-10-5363] was a two-stage longitudinal clinical study which included a first stage pro study and a second stage RCT. Therefore, the first stage pro study was defined as Yin et al (2013a)[@b20-ott-10-5363] and the second stage RCT was defined as Yin et al (2013b)[@b20-ott-10-5363].\
**Abbreviations:** CI, confidence interval; HR, hazard ratio; IV, inverse variance; NAs, nucleoside analogs; RFS, recurrence-free survival; SE, standard error.](ott-10-5363Fig6){#f6-ott-10-5363}

![Funnel plot for the results from included studies comparing RFS in HBV-related HCC patients who received antiviral therapy or no treatment.\
**Abbreviations:** HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HR, hazard ratio; RFS, recurrence-free survival; SE, standard error.](ott-10-5363Fig7){#f7-ott-10-5363}

###### 

Baseline characteristics of the studies included for meta-analysis

  Study                                                                             Study type   NA type    Arms        Cases               Age (years)[a](#tfn1-ott-10-5363){ref-type="table-fn"}   Gender (M/F)   HBV DNA level (log copies/mL)[a](#tfn1-ott-10-5363){ref-type="table-fn"}   HBeAg (±)                    Tumor size (cm)[a](#tfn1-ott-10-5363){ref-type="table-fn"}   No of tumors (S/M)   Tumor stage[b](#tfn2-ott-10-5363){ref-type="table-fn"}   Child--Pugh (A/B/C)   Follow-up duration (months)[a](#tfn1-ott-10-5363){ref-type="table-fn"}   Quality score
  --------------------------------------------------------------------------------- ------------ ---------- ----------- ------------------- -------------------------------------------------------- -------------- -------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------------ -------------------- -------------------------------------------------------- --------------------- ------------------------------------------------------------------------ ----------------------------------------------
  Chan et al (2011)[@b12-ott-10-5363]                                               Pro--retro   LAM, ETV   Treatment   42                  57                                                       31/11          N/A                                                                        N/A                          9.3                                                          N/A                  11/14/16/0 (AJCC)                                        42/0/0                N/A                                                                      4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           94           55         74/20       N/A                 N/A                                                      9.0            N/A                                                                        28/18/48/0 (AJCC)            84/10/0                                                      N/A                                                                                                                                                                          
  Chen et al (2016)[@b22-ott-10-5363]                                               Retro        LAM, ETV   Treatment   192                 47                                                       172/20         N/A                                                                        48/144                       4.7                                                          176/16               151/41/0 (TNM)                                           192/0/0               74[d](#tfn4-ott-10-5363){ref-type="table-fn"}                            4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           253          49         218/35      N/A                 35/218                                                   5.4            232/21                                                                     215/38/0 (TNM)               253/0/0                                                                                                                                                                                                                                   
  Chen (2015)[@b24-ott-10-5363]                                                     Pro          LAM        Treatment   45                  52.2                                                     39/6           N/A                                                                        N/A                          N/A                                                          37/8                 38/5/2/0 (AJCC)                                          41/4/0                N/A                                                                      4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           40           51.9       36/4        N/A                 N/A                                                      N/A            35/5                                                                       34/5/1/0 (AJCC)              38/2/0                                                       N/A                                                                                                                                                                          
  Cheng et al (2011)[@b35-ott-10-5363]                                              Retro        LAM        Treatment   50                  45.3                                                     38/12          5.56 (5.53--5.64)                                                          N/A                          N/A                                                          N/A                  N/A                                                      N/A                   N/A                                                                      4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           43           42.2       32/11       5.68 (5.50--5.83)   N/A                                                      N/A            N/A                                                                        N/A                          N/A                                                          N/A                                                                                                                                                                          
  Chong et al (2015)[@b13-ott-10-5363]                                              Pro--retro   LAM, ETV   Treatment   254                 55                                                       222/32         N/A                                                                        42/212                       3.5                                                          198/56               168/50/34/2 (AJCC)                                       243/10/1              39.2 (0.2--163.9)                                                        5[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  ADV, LdT                                                                          Control      150        56          125/25              N/A                                                      12/138         3.8                                                                        118/32                       97/26/27/0 (AJCC)                                            145/4/1              43.3 (0.1--151.2)                                                                                                                                       
  Ding et al (2014)[@b36-ott-10-5363]                                               Retro        ETV        Treatment   74                  47.2                                                     56/18          5.21                                                                       N/A                          N/A                                                          N/A                  N/A                                                      54/20/0               N/A                                                                      4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           39           46.5       30/9        5.02                N/A                                                      N/A            N/A                                                                        N/A                          31/8/0                                                       N/A                                                                                                                                                                          
  Fang et al (2012)[@b25-ott-10-5363]                                               Retro        LAM        Treatment   26                  48.9                                                     20/6           6.38                                                                       N/A                          N/A                                                          N/A                  N/A                                                      N/A                   41                                                                       4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           30           50.0       23/7        6.55                N/A                                                      N/A            N/A                                                                        N/A                          N/A                                                          20                                                                                                                                                                           
  Huang et al (2015)[@b14-ott-10-5363]                                              RCT          ADV        Treatment   100                 50.6                                                     90/10          N/A                                                                        51/49                        4.9                                                          100/0                8/60/0 (BCLC \[0/A/B\])                                  100/0/0               60 (4--70)[d](#tfn4-ott-10-5363){ref-type="table-fn"}                    3[e](#tfn5-ott-10-5363){ref-type="table-fn"}
  Control                                                                           100          50.5       89/11       N/A                 50/50                                                    5.1            100/0                                                                      8/59/0 (BCLC \[0/A/B\])      100/0/0                                                                                                                                                                                                                                   
  Huang et al (2016)[@b26-ott-10-5363]                                              Retro        LAM, ETV   Treatment   45                  N/A                                                      N/A            4.72                                                                       N/A                          N/A                                                          N/A                  N/A                                                      45/0/0                11 (3--34)[d](#tfn4-ott-10-5363){ref-type="table-fn"}                    4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  ADV                                                                               Control      33         N/A         N/A                 4.25                                                     N/A            N/A                                                                        N/A                          N/A                                                          33/0/0                                                                                                                                                                       
  Ke et al (2013)[@b15-ott-10-5363]                                                 Retro        LAM        Treatment   141                 48.9                                                     129/12         4.97                                                                       15/126                       4.5                                                          102/39               107/23/11 (BCLC \[A/B/C\])                               141/0/0               24 (2--65)                                                               5[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           141          49.7       127/14      4.78                16/125                                                   5.0            107/34                                                                     105/26/10 (BCLC \[A/B/C\])   141/0/0                                                      23 (1--73)                                                                                                                                                                   
  Li et al (2010)[@b16-ott-10-5363]                                                 Pro          LAM, ADV   Treatment   43                  46                                                       34/9           6.49 (4.04--7.38)                                                          38/5                         7.1                                                          N/A                  9/17/17 (TNM)                                            28/14/1               12                                                                       4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           36           45         30/6        7.27 (3.45--8.32)   27/9                                                     8.5            N/A                                                                        4/10/22 (TNM)                21/12/3                                                      12                                                                                                                                                                           
  Lin et al (2016)[@b27-ott-10-5363]                                                Retro        ETV        Treatment   35                  54.2                                                     26/9           7.48                                                                       N/A                          N/A                                                          N/A                  N/A                                                      28/7/0                54                                                                       4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           25           2.5        20/5        6.94                N/A                                                      N/A            N/A                                                                        N/A                          20/5/0                                                       38                                                                                                                                                                           
  Qian et al (2016)[@b28-ott-10-5363]                                               Retro        LAM, ADV   Treatment   70                  N/A                                                      58/12          6.70                                                                       N/A                          6.5                                                          N/A                  N/A                                                      70/0/0                N/A                                                                      4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           65           N/A        52/13       6.71                N/A                                                      6.6            N/A                                                                        N/A                          65/0/0                                                       N/A                                                                                                                                                                          
  Su et al (2013)[@b17-ott-10-5363]                                                 Retro        LAM, ETV   Treatment   62                  52                                                       56/6           5.89 (4.83--7.15)                                                          9/53                         2.7                                                          48/14                40/15/5 (BCLC \[A/B/C\])                                 N/A                   N/A                                                                      4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           271          58         232/39      5.48 (4.09--7.83)   28/243                                                   4.2            144/127                                                                    142/83/44 (BCLC \[A/B/C\])   N/A                                                          N/A                                                                                                                                                                          
  Tian et al (2015)[@b29-ott-10-5363]                                               Retro        LAM, ETV   Treatment   29                  57.8                                                     18/11          4.7                                                                        N/A                          2.8                                                          11/18                N/A                                                      25/4/0                28.6[d](#tfn4-ott-10-5363){ref-type="table-fn"}                          4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  ADV                                                                               Control      21         58.3        14/7                6.1                                                      N/A            3.4                                                                        8/13                         N/A                                                          18/3/0                                                                                                                                                                       
  Wang et al (2015)[@b30-ott-10-5363]                                               Retro        LAM, ETV   Treatment   76                  53.7                                                     58/18          5.46                                                                       N/A                          6.1                                                          64/12                35/30/11 (TNM)                                           N/A                   30.3                                                                     4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  ADV                                                                               Control      80         51.3        57/23               5.40                                                     N/A            5.5                                                                        71/9                         32/28/10 (TNM)                                               N/A                  18.4                                                                                                                                                    
  Wei et al (2016)[@b23-ott-10-5363]                                                Retro        LAM, ADV   Treatment   86                  50.8                                                     79/7           6.9 (2.0--8.8)                                                             14/72                        8.0                                                          27/59                0/36/50 (TNM)                                            82/4/0                30.6 (3.3--73.2)[d](#tfn4-ott-10-5363){ref-type="table-fn"}              4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           40           50.0       35/5        5.7 (2.0--6.7)      6/34                                                     8.9            15/25                                                                      0/22/18 (TNM)                39/1/0                                                                                                                                                                                                                                    
  Wu et al (2012)[@b18-ott-10-5363]                                                 Retro        LAM, ETV   Treatment   518                 54.4                                                     435/83         N/A                                                                        N/A                          N/A                                                          N/A                  N/A                                                      N/A                   32                                                                       4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  LdT                                                                               Control      4,051      54.6        3,335/716           N/A                                                      N/A            N/A                                                                        N/A                          N/A                                                          N/A                  26                                                                                                                                                      
  Xu et a1 (2016)[@b31-ott-10-5363]                                                 Retro        N/A        Treatment   29                  N/A                                                      N/A            N/A                                                                        N/A                          N/A                                                          N/A                  N/A                                                      N/A                   N/A                                                                      4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           82           N/A        N/A         N/A                 N/A                                                      N/A            N/A                                                                        N/A                          N/A                                                          N/A                                                                                                                                                                          
  Yang et al (2010)[@b32-ott-10-5363]                                               Retro        LAM        Treatment   30                  22/8                                                     N/A            N/A                                                                        N/A                          N/A                                                          N/A                  27/2/1 (TNM)                                             29/1/0                26.2[d](#tfn4-ott-10-5363){ref-type="table-fn"}                          4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           30           23/7       N/A         N/A                 N/A                                                      N/A            N/A                                                                        21/7/2 (TNM)                 26/4/0                                                                                                                                                                                                                                    
  Yang et al (2012)[@b19-ott-10-5363]                                               Pro          LAM, ETV   Treatment   142                 N/A                                                      N/A            N/A                                                                        N/A                          N/A                                                          N/A                  N/A                                                      N/A                   49.1[d](#tfn4-ott-10-5363){ref-type="table-fn"}                          4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  ADV                                                                               Control      188        N/A         N/A                 N/A                                                      N/A            N/A                                                                        N/A                          N/A                                                          N/A                                                                                                                                                                          
  Yao et al (2016)[@b33-ott-10-5363]                                                Retro        LAM, ADV   Treatment   76                  53.9                                                     54/22          5.43                                                                       N/A                          N/A                                                          N/A                  N/A                                                      N/A                   30.4                                                                     4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           80           52.3       55/25       5.40                N/A                                                      N/A            N/A                                                                        N/A                          N/A                                                          18.5                                                                                                                                                                         
  [\*](#tfn6-ott-10-5363){ref-type="table-fn"}Yin et al (2013a)[@b20-ott-10-5363]   Pro          LAM, ETV   Treatment   215                 50.1                                                     194/21         4.51                                                                       80/135                       N/A                                                          184/31               6/159/50 (BCLC \[0/A/B\])                                209/6/0               24[d](#tfn4-ott-10-5363){ref-type="table-fn"}                            5[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  ADV                                                                               Control      402        50.3        336/66              3.82                                                     100/302        N/A                                                                        351/51                       6/296/98 (BCLC \[0/A/B\])                                    392/10/0                                                                                                                                                                     
  [\*](#tfn6-ott-10-5363){ref-type="table-fn"}Yin et al (2013b)[@b20-ott-10-5363]   RCT          LAM, ETV   Treatment   81                  47.9                                                     74/7           4.88                                                                       41/40                        N/A                                                          71/10                4/67/10 (BCLC \[0/A/B\])                                 80/1/0                40[d](#tfn4-ott-10-5363){ref-type="table-fn"}                            3[e](#tfn5-ott-10-5363){ref-type="table-fn"}
  ADV                                                                               Control      82         49.4        70/12               4.57                                                     26/56          N/A                                                                        64/18                        2/58/22 (BCLC \[0/A/B\])                                     82/0/0                                                                                                                                                                       
  Zhang (2015)[@b34-ott-10-5363]                                                    Pro          LAM        Treatment   45                  52.2                                                     39/6           N/A                                                                        N/A                          N/A                                                          37/8                 38/5/2 (TNM)                                             41/4/0                N/A                                                                      4[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           40           51.9       36/4        N/A                 N/A                                                      N/A            35/5                                                                       34/5/1 (TNM)                 38/3/0                                                       N/A                                                                                                                                                                          
  Zhang et al (2014)[@b21-ott-10-5363]                                              Retro        ETV        Treatment   40                  N/A                                                      26/14          N/A                                                                        N/A                          4.6                                                          40/0                 N/A                                                      33/6/1                N/A                                                                      5[c](#tfn3-ott-10-5363){ref-type="table-fn"}
  Control                                                                           47           N/A        31/16       N/A                 N/A                                                      4.8            47/0                                                                       N/A                          37/10/0                                                      N/A                                                                                                                                                                          

**Notes:**

Mean, median, or median (range).

Tumor stage containing AJCC with form (I/II/III/IV), TNM with form (I/II/III), and BCLC (0/A/B or A/B/C).

Modified Newcastle--Ottawa scale (0--6 stars).

The follow-up duration of all patients in the study.

Jadad scale (0--5 points).

Study of Yin et al (2013)[@b20-ott-10-5363] was a two-stage longitudinal clinical study which included a first stage pro study and a second stage RCT. Therefore, the first stage pro study was defined as Yin et al (2013a)[@b20-ott-10-5363] and the second stage RCT was defined as Yin et al (2013b)[@b20-ott-10-5363].

**Abbreviations:** ADV, adefovir dipivoxil; AJCC, American Joint Committee on Cancer; BCLC, Barcelona clinic Liver Cancer; ETV, entecavir; HBeAg, Hepatitis B e-antigen; HBV, hepatitis B virus; LAM, lamivudine; LdT, telbivudine; M/F, male/female; NA, nucleoside analog; N/A, not available; Pro, prospective; RCT, randomized controlled trial; Retro, retrospective; S/M, single/multiple.
